Figure 1






Figure 2

NIH3T3-pLXSN-poly



72A1 MAB154

NIH3T3-Axl-cl.7



72A1 MAB154

Figure 3




pcDNA3
hAxl
mAxl
cyAxl
hSky
hMer
30
25
20
15
10
5
0
mouse PE
rat PE
1D5
11D5
11B7
10D12
6E7
2A1
11D7
12B7
control or anti-Axl Abs

Figure 4

A NIH3T3-Axl cl.7



B NCI-H292




Figure 5




unstimulated 400ng/ml mGAS6
absorbance
1,4
1,2
1,0
0,8
0,6
0,4
0,2
0,0
no
1D5
11D5
11B7
2A1
control or anti-Axl antibodies

Figure 6

A NIH3T3-Axl cl.7



B CaLu-1






Figure 7

11B7 (rIgG2a)




	50ng/ml	100ng/ml	300ng/ml	500ng/ml	1µg/ml
unst.	13	-16	-11	-11	-9
Gas6	-87	-110	-109	-112	-114

ch11B7 (hIgG2)




	50ng/ml	100ng/ml	300ng/ml	500ng/ml	1µg/ml
unst.	-3	-25	-6	-14	-7
Gas6	-54	-115	-102	-109	-104

11D5 (rIgG2a)



	50ng/ml	100ng/ml	300ng/ml	500ng/ml	1µg/ml	5µg/ml	10µg/ml AB
unstim.	2	-2	-1	2	1	-1	3
400ng/ml GAS6	0	-15	-44	-69	-92	-86	-93

ch11D5 (hIgG2)



	50ng/ml	100ng/ml	300ng/ml	500ng/ml	1µg/ml	5µg/ml	10µg/ml AB
unstim.	3	1	-2	2	2	6	11
400ng/ml GAS6	0	-12	-27	-49	-77	-84	-89

Figure 8



PBS 1D5 biot. 11B7 biot. 11D5 biot. 6E7 biot. 10D12 biot. 11D7 biot. 2A1 biot.
fluorescence
3500000
3000000
2500000
2000000
1500000
1000000
500000
0
PBS
1D5
11B7
11D5
6E7
PBS
1D5
10D12
11D7
2A1
unbiotinylated control or anti-Axl antibodies

Figure 9



noAB
1D5
2A1 rat
11D7 rat
11D5 rat
11B7 rat
6E7 rat
10D12 rat
chn11D5 IgG2
chn11B7 IgG2
Erbitux
Sutent

Figure 10



☐ unstimulated ☐ 400ng/ml mGas6
fluorescence
40000
35000
30000
25000
20000
15000
10000
5000
0
PBS
4A6
11B7
2A1
control or anti-Axl antibodies

Figure 11



unstimulated
400ng/ml mGAS6
fluorescence
350000
300000
250000
200000
150000
100000
50000
0
72A1
11D5
11B7
2A1
control or anti-Axl antibodies

Figure 12





□ unstimulated □ 400ng/ml mGAS6
caspase-3/7 activity
180000
160000
140000
120000
100000
80000
60000
40000
20000
0
no Ab
1D5
11B7
11D5
11D7
2A1
control or anti-Axl antibodies


Figure 13

A 11B7





B 11D5






Figure 14



Mean tumor luciferase activity (photons/s)
2.0×10⁸
1.8×10⁸
1.5×10⁸
1.3×10⁸
1.0×10⁸
7.5×10⁷
5.0×10⁷
2.5×10⁷
0
Control
Anti-Axl mAb 11B7
Sutent
Taxotere
Treatment start
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
Time (days)

Figure 15




Luciferase activity
(LU/µg protein)
10⁶
10⁵
10⁴
10³
10²
10¹
10⁰
1D5
11B7
Sutent
Taxotere

Figure 16


A

	Intensity ≥ 1	
	Tumor	Adjacent
Breast	3/3	0/3
Colon	3/11	0/11
Lung	2/9	0/9
Kidney	0/10	0/10
Fol. Lymphoma	0/12	0/3
Skin/Melanoma	1/13	0/12
Ovary	4/11	0/9
Prostate	0/11	0/9
Pancreas	2/9	0/11
Esophagus	4/10	0/10
Barrett	4/11	0/9
Stomach	6/10	0/7
Bladder	8/10	0/10
Cervix	7/9	0/9
Liver	3/9	0/7
Thyroid	5/9	0/11
Head & Neck	8/20	0/17

B




Breast cancer



Gastric signet ring cell carcinoma

Figure 17


A 11B7 (rIgG1)



	50ng/ml	100ng/ml	300ng/ml	750ng/ml	1µg/ml	10µg/ml
unst.	11	10	20	27	28	32
Gas6	-5	-15	-70	-76	-81	-84

antibody treatment

B ch11B7 (hIgG1)




	50ng/ml	100ng/ml	300ng/ml	750ng/ml	1µg/ml	10µg/ml
unst.	13	26	34	38	34	34
Gas6	-25	-32	-73	-76	-78	-77

antibody treatment

Figure 18

A 11B7 (rIgG1)



B ch11B7 (hIgG1)




Figure 19




Control mAb
Anti-Axl mAb
11B7
100 µM
Doxorubicin
150 µM
Doxorubicin
200 µM
Doxorubicin


Figure 20

A



area of colonies,
absolute numbers

B



area of colonies,
relative inhibition